Intellectual property related to the Australian Life Sciences sector

Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (22 August 2018)

Below are what we consider to have been the most notable PCT patent applications relevant to the Life Sciences sector in Australia that have been published since 27 August 1998. For PCT patent applications prior to that date click here.

WO/2016/061619, A method of treatment, Hexima, 28 April 2016
WO/2016/061615, Methods of reducing mammographic breast density and/or breast cancer risk, Chavah, 28 April 2016
WO/2016/058056, Novel imaging composition and uses thereof, University of Melbourne, 21 April 2016
WO/2016/054671, Selenosugars and therapeutic uses thereof, Carl Schiesser, Corin Storkey and Michael Davies, 14 April 2016
WO/2016/049677, Method of treating cancer, Walter and Eliza Hall Institute of Medical Research, 7 April 2016
WO/2016/033660, Antiviral agents and uses thereof, Griffith University, 10 March 2016
WO/2015/196250, Lipid comprising docosapentaenoic acid, Commonwealth Scientific and Industrial Research Organisation, Grains Research and Development Corporation and Nuseed Pty Ltd, 30 December 2015
WO/2015/191595, A novel formulation of meloxicam, iCeutica Pty Ltd, 17 December 2015
WO/2015/184509, Methods of treating neurodevelopmental diseases and disorders, Deakin University and Florey Institute of Neuroscience and Mental Health, 10 December 2015
WO/2015/181641, Combination of lenalidomide or pomalidomide and CD38 antibody-attenuated interferon-alpha constructs, and the use thereof, Teva Pharmaceuticals Australia, 3 December 2015
WO/2015/159103, Piperazine derivatives for treating disorders, University of Nottingham and Newsouth Innovations, 22 October 2015
WO/2015/149105, Method for treating Chronic Lymphocytic Leukemia, Bionomics Ltd, 8 October 2015
WO/2015/135024, Adjuvant therapy to standard of care (SOC) diuretic treatment, Madeleine Pharmaceuticals Pty Ltd, 17 September 2015
WO/2015/117199, Anti-metalloprotease antibody for diagnosis and treatment of cancers, Monash University, Memorial Sloan-Kettering Cancer Centre and Ludwig Institute for Cancer Research, 13 August 2015
WO/2015/109362, Method for reducing total gas production and/or methane production in a ruminant animal, Commonwealth Scientific and Industrial Research Organisation, Meat and Livestock Australia Ltd and James Cook University, 30 July 2015
WO/2015/089587, Lipid comprising long chain polyunsaturated fatty acids, Commonwealth Scientific and Industrial Research Organisation, Nuseed Pty Ltd and Grains Research and Development Corporation, 25 June 2015
WO/2015/077845, Method of treating nephropathy, CSL Ltd, 4 June 2015
WO/2015/074115, Prevention and treatment of toxicosis, Meat and Livestock Australia and Charles Sturt University, 28 May 2015
WO/2015/073803, Neurodegenerative disorders and methods of treatment and diagnosis thereof, University of Queensland, 21 May 2015
WO/2015/061839, Cell culture method, Isopogen Pty Ltd, 7 May 2015
WO/2015/061832, Pharmaceutical combinations for the treatment of cancer, PharmAust Ltd and University of New South Wales, 7 May 2015
WO/2015/061826, Novel scorpion toxin analogue and method for treating autoimmune diseases, Monash University, 7 May 2015
WO/2015/049589, Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma, EnGeneIC, 9 April 2015
WO/2015/039173, Compositions for the treatment of hypertension and/or fibrosis, Vectus Biosystems, 26 March 2015
WO/2015/037747, Anticancer agent comprising aminoacetonitrile compound as active ingredient, Nihon Nohyaku Co. (Japan) and PharmAust Ltd, 19 March 2015
WO/2015/027296, A method of treatment, University of Melbourne, 5 March 2015
WO/2015/013581, Combinatorial methods to improve the therapeutic benefit of bisantrene, Race Oncology, 29 January 2015
WO/2015/013579, Compositions to improve the therapeutic benefit of bisantrene, Update Pharma, 29 January 2015
WO/2015/006803, UV absorbing compounds, compositions comprising same and uses thereof, Coral Sunscreen Pty Ltd, 22 January 2015
WO/2014/194362, Process for preparing Apolipoprotein A-I (APO A-I), CSL Ltd, 11 December 2014
WO/2014/179831, Dosage projectile for remotely treating an animal, Smartvet, 13 November 2014
WO/2014/179754, High osmolarity antimicrobial composition containing one or more organic solvents, Next Science, 6 November 2014
WO/2014/178820, Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b, Teva Pharmaceuticals Australia Pty Ltd, 6 November 2014
WO/2014/176634, Methods for treating bacterial infections, Neoculi, 6 November 2014
WO/2014/176394, Vitamin D receptor/SMAD genomic circuit gates fibrotic response, Salk Institute for Biological Studies and University of Sydney, 30 October 2014
WO/2014/173873, Complex, CSL Ltd, 30 October 2014
WO/2014/140797, MicroRNA-based approach to treating malignant pleural mesothelioma, Asbestos Diseases Research Foundation, 18 September 2014
WO/2014/138796, Dosage regimen for therapeutic method, Madeleine Pharmaceuticals, 18 September 2014
WO/2014/134689, Polymer conjugate for delivery of a bioactive agent, Polyactiva, 12 September 2014
WO/2014/124487, Ligand binding molecules and uses thereof, Vegenics, 21 August 2014
WO/2014/121342, Methods of treating topical microbial infections, Luoda Pharma, 14 August 2014
WO/2014/117220, Anti-CD83 antibodies and use thereof, Transbio with the University of Queensland and the University of California (US), 7 August 2014
WO/2014/100852, Inhibition of cancer growth and metastasis, Royal Melbourne Institute of Technology and Abregen Pty Ltd, 3 July 2014
WO/2014/094043, Methods of generating cells with multilineage potential, University of New South Wales, 26 June 2014
WO/2014/078900, Anti-pathogenic methods, Hexima, 30 May 2014
WO/2014/075125, Soluble mediator, Walter and Eliza Hall Institute of Medical Research, 22 May 2014
WO/2014/071449, Neuroactive steroids and their use to facilitate neuroprotection, Goodchild Investments, 15 May 2014
WO/2014/066951, Dental compositions, Ozdent, 8 May 2014
WO/2014/066943, Reconstituted HDL formulation, CSL Ltd, 8 May 2014
WO/2014/063198, A radioisotope concentrator, Cyclopharm, 1 May 2014
WO/2014/059489, Improved human herpesvirus immunotherapy, Queensland Institute of Medical Research, 24 April 2014
WO/2014/059484, Cancer therapy using miRNAs, University of Western Australia, 24 April 2014
WO/2014/059429, Small molecules inhibiting oncoprotein Myc, Health Research (US), Panacela Labs (US), Children's Cancer Institute, 17 April 2014
WO/2014/059034, NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation, Harvard University and University of New South Wales, 17 April 2014
WO/2014/056025, Improved process for purifying lactoferrin from milk and products thereof, Murray Goulburn Co-Operative Co., 17 April 2014
WO/2014/043743, Viscous haemostatic compostions and method of treatment, Eupharma, 27 March 2014
WO/2014/041425, Daptomycin formulations and uses thereof, Hospira Australia, 20 March 2014
WO/2014/036608, Methods and products for preventing and/or treating metastatic cancer, Adelaide Research & Innovation, 13 March 2014
WO/2014/032082, Modified human rotaviruses and uses therefor, Murdoch Childrens Research Institute, 6 March 2014
WO/2014/028968, Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof, Peter Maccallum Cancer Institute, 27 February 2014
WO/2014/026243, VEGFR3 inhibitors, Cancer Therapeutics CRC, 20 February 2014
WO/2014/026242, VRGFR3 inhibitors, Cancer Therapeutics CRC, 20 February 2014
WO/2014/022879, Compounds for the treatment of mTOR pathway related diseases, Pitney Pharmaceuticals, 13 February 2014
WO/2014/019025, EpCAM aptamer for detection of cancer stem cells, Deakin University, 6 February 2014
WO/2014/008542, Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders, Brien Holden Vision Institute, 16 January 2014
WO/2014/005194, Immunological reagents and uses therefor, University of Melbourne, Monash University and University Of Queensland, 9 January 2014
WO/2014/000033, Polymer-NSAID conjugate, Polyactiva, 3 January 2014
WO/2013/192566, Itraconazole compositions and dosage forms, and methods of using the same, Mayne Pharma, 27 December 2013
WO/2013/185184, Production of long chain polyunsaturated fatty acids in plant cells, Commonwealth Scientific and Industrial Research Organisation, Grains Research and Development Corporation and Nuseed Pty Ltd, 19 December 2013
WO/2013/185178, Nanoemulsions, University of Queensland, 19 December 2013
WO/2013/181713, Release media, University of Queensland, 12 December 2013
WO/2013/181694, Compositions and methods for treating Crohn's disease and related conditions and infections, Gaurav Agrawal, 12 December 2013
WO/2013/177608, Method of treating Scedosporium spp. infection, Biodiem Ltd, 5 December 2013
WO/2013/173874, Composition and method for management of diabetes or pre-diabetes, Omniblend Innovation, 28 November 2013
WO/2013/173129, Treatment of AMD using AAV sFlt-1, Avalanche Australia Pty Ltd and Lions Eye Institute, 21 November 2013
WO/2013/170317, Liquid formulation, Luoda Pharma Pty Ltd, 21 November 2013
WO/2013/170315, A method of treatment and agents useful for same, Paranta Biosciences Ltd, 21 November 2013
WO/2013/170305, Cellular vaccine and method of inducing an immune response in a subject, University of Adelaide, 21 November 2013
WO/2013/166555, Methods of treating cancer using angiogenin or an angiogenin agonist, Murray Goulburn Co-Operative Co. Ltd, 14 November 2013
WO/2013/166545, 6-oxopurine phosphoribosyltransferase inhibitors, University of Queensland and Institute of Organic Chemistry and Biochemistry, 14 November 2013
WO/2013/152392, Viral polymerase inhibitors, Biota, 17 October 2013
WO/2013/152391, Viral polymerase inhibitors, Biota, 17 October 2013
WO/2013/150382, Herbal compositions for the prevention or treatment of Benign Prostatic Hyperplasia and related disorders, Tracey Seipel, 10 October 2013
WO/2013/150292, Composition for the treatment of inflammatory and immune disorders, Eaglepharma, 10 October 2013
WO/2013/138863, Kinase inhibitors for the treatment of cancer, NewSouth Innovations, 26 September 2013
WO/2013/134822, Method for treating inflammation, James Cook University, 19 September 2013
WO/2013/128283, Inhalable pharmaceutical compositions, iCeutica Pty Ltd, 6 September 2013
WO/2013/124666, Tumour Necrosis Factor receptor fusion proteins and methods of using the same, Nexvet, 29 August 2013
WO/2013/113774, Factor XII inhibitors for the treatment of neurological inflammatory disorders, CSL Ltd, Julius-Maximilians-Universitaet-Wuerzburg and Westfaelische Wilhelms-Universitaet Muenster, 8 August 2013
WO/2013/113074, Combination therapy comprising a growth hormone variant and an oligonucleotide targeted to the growth hormone receptor, Antisense Therapeutics, 8 August 2013
WO/2013/091004, Prevention and treatment of Mycobacterium infection, University of Sydney and Centenary Institute of Cancer Medicine and Cell Biology, 27 June 2013
WO/2013/091001, A peptide-hydrogel composite, University of Sydney, 27 June 2013
WO/2013/090989, Method of treating inflammatory bowel disease, CSL Ltd, 27 June 2013
WO/2013/088250, Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors, EnGeneIC, 20 June 2013
WO/2013/085904, Oral spray formulations and methods for administration of sildenafil, Suda Pharmaceuticals, 13 June 2013
WO/2013/082656, Cage amine ligands for metallo-radiopharmaceuticals, University of Melbourne, 13 June 2013
WO/2013/082655, Functionalisation of cage amine ligands for metallo-radiopharmaceuticals, University of Melbourne, 13 June 2013
WO/2013/078500, Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug, Jurox Pty Ltd, 6 June 2013
WO/2013/075172, Improved synergistic anti-diabetic compositions, Ozstar Therapeutics, 30 May 2013
WO/2013/071355, Soluble mediator, Walter and Eliza Hall Institute of Medical Research, 23 May 2013
WO/2013/067578, Modulators of C3a receptors, University of Queensland, 16 May 2013
WO/2013/059886, PAT-LM1 epitopes and methods for using same, Patrys, 2 May 2013
WO/2013/057219, Method for improving the stability of purified Factor VIII after reconstitution, CSL Ltd, 25 April 2013
WO/2013/036998, Treatment of bone diseases, University of Sydney and Nepean Blue Mountains Local Health District, 21 March 2013
WO/2013/026099, Fn14 binding proteins and uses thereof, Transbio, 28 February 2013
WO/2013/020183, Immunogenic compositions and methods therefor, University of Queensland, 14 February 2013
WO/2013/020164, Compounds for treating Respiratory Syncytial Virus infections, Biota, 14 February 2013
WO/2013/014092, Inhibitory anti-factor XII/XIIa monoclonal antibodies and their uses, CSL Ltd, 31 January 2013
WO/2013/013273, Modulators of protease activated receptors, University of Queensland, 31 January 2013
WO/2013/011021, Use of c-Fms antagonists, University of Melbourne and Morphosys, 24 January 2013
WO/2013/010225, Enzymes for degrading organophosphates, Commonwealth Scientific and Industrial Research Organisation, 24 January 2013
WO/2013/006917, Disinfecting formulations and uses thereof. Sunnywipes Pty Ltd, 17 January 2013
WO/2013/003904, Recombinant low virulence Bovine Herpesvirus 1 (BOHV-1) vaccine vectors, Queensland Department of Agriculture, Fisheries and Forestry, and Meat & Livestock Australia Ltd, 10 January 2013
WO/2013/003895, Combination therapy, Biosceptre International, 10 January 2013
WO/2012/171057, Antibodies against G-CSFR and uses thereof, CSL Ltd, 20 December 2012
WO/2012/167309, Macromolecules, Starpharma, 13 December 2012
WO/2012/166998, Compositions for sequential administration of opioid receptor agonists, QRxPharma, 6 December 2012
WO/2012/162753, Biocompatible material and uses thereof, University of Sydney, 6 December 2012
WO/2012/162731, Blood stage malaria vaccine, Griffith University and La Trobe University, 6 December 2012
WO/2012/155203, Regulation of nitric oxide release and biofilm development, University of New South Wales and University of Wollongong, 22 November 2012
WO/2012/155172, Method of treatment or prophylaxis of bacterial vaginosis, Starpharma, 22 November 2012
WO/2012/153126, Therapeutic canine immunoglobulins and methods of using the same, Nexvet, 15 November 2012
WO/2012/153122, Anti-nerve growth factor antibodies and methods of preparing and using the same, NVIP Pty Ltd, 15 November 2012
WO/2012/153121, Anti-nerve growth factor antibodies and methods of preparing and using the same, Nexvet, 15 November 2012
WO/2012/151640, Methods for preparing naphthyridines, Bionomics, 15 November 2012
WO/2012/142662, Modified variable domain molecules and methods for producing and using them, Garvan Institute of Medical Research, 26 October 2012
WO/2012/122604, Pharmaceutical compositions and topical use thereof, Regeneus, 20 September 2012
WO/2012/122590, Antibody recognizing n-domain of midkine, Cellmid, 20 September 2012
WO/2012/122586, New composition, Phosphagenics and Mastitis Management Australia, 20 September 2012
WO/2012/119203, Gene expression and eradication system in Helicobacter pylori, Ondek Pty Ltd, 13 September 2012
WO/2012/116391, Cosmetic or pharmaceutical formulation, Wendy Lien, 7 September 2012
WO/2012/113017, Control of insect pests, Innovate Ag Pty Ltd, 30 August 2012
WO/2012/110773, FAK inhibitors, Cancer CRC, 23 August 2012
WO/2012/109445, Hybrid opioid compounds and compositions, QRxPharma, 16 August 2012
WO/2012/106761, Sugar extracts, Horizon Science, 16 August 2012
WO/2012/103588, Treatment of bone marrow edema (oedema) with polysulfated polysaccharides, Paradigm Biopharma, 9 August 2012
WO/2012/103583, Positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor and uses thereof, Bionomics, 9 August 2012
WO/2012/096866, Use of beta-adrenergic inverse agonists for smoking cessation, Inverseon, 19 July 2012
WO/2012/094703, Combination therapy, Dimerix, 19 July 2012
WO/2012/079121, Improved mineral based composition and methods of use, Tuffrock Technology Pty Ltd, 21 June 2012
WO/2012/075534, Methods for forming miniemulsions and use thereof for delivering bioactive agents, NS Technologies Pty Ltd, 14 June 2012
WO/2012/071611, Histone inhibition, Australian National University, 7 June 2012
WO/2012/068637, Compositions and methods, Macfarlane Burnet Institute for Medical Research and Public Health, 31 May 2012
WO/2012/068627, Peptides for the specific binding of RNA targets, University of Western Australia, 31 May 2012
WO/2012/068619, Preparation and/or formulation of proteins cross-linked with polysaccharides, Elastagen, 31 May 2012
WO/2012/068612, Methods of treating eye diseases associated with inflammation and vascular proliferation, Fibrotech Therapeutics Pty Ltd, 31 May 2012
WO/2012/061882, Treatment and prevention of malaria, Walter and Eliza Hall Institute of Medical Research, 18 May 2012
WO/2012/054978, Novel anti-cancer agents, Ludwig Institute for Cancer Research and Walter And Eliza Hall Institute Of Medical Research, 3 May 2012
WO/2012/052205, Selective targeting of the CD40/Max-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis, Universitätsklinikum Freiburg and Baker IDI Heart and Diabetes Institute, 26 April 2012
WO/2012/037612, Novel immunostimulatory method, University of Melbourne, 29 March 2012
WO/2012/037239, Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia, QRxPharma, 22 March 2012
WO/2012/035558, A synthetic immunogen useful for generating long lasting immunity and protection against pathogens, Council Of Scientific & Industrial Research and University Of Melbourne, 22 March 2012
WO/2012/034194, Method for mobilizing stem and/or progenitor cells, Antisense Therapeutics, 22 March 2012
WO/2012/031333, Companion animal treatments, Biosceptre International, 15 March 2012
WO/2012/031326, Single chain relaxin polypeptides, Howard Florey Institute of Experimental Physiology and Medicine and University Of Queensland, 15 March 2012
WO/2012/023051, Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder, Immuron, 23 February 2012
WO/2012/021942, TAM receptors and TAM receptor ligands in detection and modulation of neuropathological disease, Florey Institute of Neuroscience and Mental Health, 23 February 2012
WO/2012/021934, Humanized anti-interleukin 3 receptor alpha chain antibodies, CSL Ltd, 23 February 2012
WO/2012/019237, Therapeutic method for treating congestive heart failure, Madeleine Pharmaceuticals Pty Ltd, 16 February 2012
WO/2012/016290, Modified Hepatitis C Virus proteins, Macfarlane Burnet Institute for Medical Research and Public Health, 9 February 2012
WO/2012/012851, Recombinant Neisseria meningitidis PorA porin proteins, Griffith University, 2 February 2012
WO/2012/012843, Modulators of protease activated receptors, University of Queensland, 2 February 2012
WO/2012/011144, Use of amino acid sequences from Mycobacterium tuberculosis or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom, Cellestis, 26 January 2012
WO/2012/010843, Salt and solvates of a tetrahydroisoquinoline derivative, Spinifex Pharmaceuticals Pty Ltd, 26 January 2012
WO/2012/009760, Anti-Il-23 heterodimer specific antibodies, Cephalon Australia Pty Ltd, 26 January 2012
WO/2012/003544, Protein kinase inhibitors and methods of treatment, Ludwig Institute for Cancer Research and Walter and Eliza Hall Institute of Medical Research, 12 January 2012
WO/2012/000055, Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease, Brien Holden Vision Institute, 5 January 2012
WO/2012/000048, A reconstituted High Density Lipoprotein formulation and production method thereof, CSL Ltd, 5 January 2012
WO/2011/160191, Compound for the treatment of enteroviruses, Biota, 29 December 2011
WO/2011/160182, Means of controlling infection persistence of Helicobacter pylori, Ondek Pty Ltd, 29 December 2011
WO/2011/160170, Stimulating immune response, Peter MacCallum Cancer Institute, 29 December 2011
WO/2011/156860, Immunotherapeutic method involving CD123 (Il-3rα) antibodies and immunostimulating complex, CSL Ltd, 22 December 2011
WO/2011/153583, Nociceptin mimetics, University of Queensland, 15 December 2011
WO/2011/150470, Vitronectin:keratinocyte growth factor chimeras, Queensland University of Technology, 8 December 2011
WO/2011/150457, Haematopoietic prostaglandin D2 synthase inhibitors, University of Queensland, 8 December 2011
WO/2011/150454, Antibodies directed to the unprocessed receptor tyrosine kinase C-MET, Monash University and Ludwig Institute for Cancer Research, 8 December 2011
WO/2011/149492, Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases, Genentech and Walter and Eliza Hall Institute of Medical Research, 1 December 2011
WO/2011/148316, Drug-delivery accessory for an implantable medical device, Cochlear, 1 December 2011
WO/2011/146981, Anti-diabetic compositions and methods, Ozstar Therapeutics, 1 December 2011
WO/2011/146978, Delivery of oral care products, International Scientific Pty Ltd, 1 December 2011
WO/2011/143706, Methods relating to an attenuated mycoplasma, Bioproperties Pty Ltd, 24 November 2011
WO/2011/140595, Immunostimulatory and vaccine compositions, 4G Vaccines Pty Ltd, 17 November 2011
WO/2011/127543, Proteins that bind PI16 and uses thereof, Transbio, 20 October 2011
WO/2011/120084, Transdermal delivery patch, Phosphagenics, 6 October 2011
WO/2011/112791, Modulating aquaporins with relaxin, University of Melbourne and University of Florida, 15 September 2011
WO/2011/112549, Temperature sensitive conjugate compositions, and uses related thereto, Emory University and Baker IDI Heart and Diabetes Institute, 15 September 2011
WO/2011/103633, Treatment or prevention of infection, Oral Health Australia Pty Ltd, 1 September 2011
WO/2011/103624, Method of treatment or prevention of hair loss or for the enhancement of hair growth, Cellmid, 1 September 2011
WO/2011/100786, Compositions and methods for targeting type 1 interferon producing cells, CSL Ltd, 25 August 2011
WO/2011/094823, Compounds for treating Respiratory Syncytial Virus infections, Biota, 11 August 2011
WO/2011/088504, Methods and compositions for improved nerve conduction velocity, Spinifex Pharmaceuticals Pty Ltd, 28 July 2011
WO/2011/088503, Anaesthetic formulation, Juliet and Colin Goodchild and Monash University, 28 July 2011
WO/2011/079349, Okadaella gastrococcus and cancer, Okada Medical Services, 7 July 2011
WO/2011/075789, Antibodies to non-functional oligomeric p2x7 receptors, Biosceptre International, 30 June 2011
WO/2011/075786, Immuno-conjugates and methods for producing them 2, Avipep Pty Ltd, 30 June 2011
WO/2011/075777, Neuronal stimulation, University of Queensland, 30 June 2011
WO/2011/075766, Antimicrobial compounds, University of Western Australia, 30 June 2011
WO/2011/069214, Methods and compositions for bone and cartilage repair, Cimtech, 16 June 2011
WO/2011/069037, Stabilization and storage of biological pharmaceutical compositions, University of North Carolina at Charlotte, Charlotte-Mecklenburg Hospital Authority, Monash University, 9 June 2011
WO/2011/068560, Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases, AbbVie and Walter Eliza Hall Institute of Medical Research, 9 June 2011
WO/2011/063477, Fibronectin: growth factor chimeras, Queensland University of Technology, 3 June 2011
WO/2011/063456, Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors, University of Western Australia, 3 June 2011
WO/2011/054030, Treatment of cancer involving mutated KRAS or BRAF genes, Cephalon Australia Pty Ltd, 12 May 2011
WO/2011/047434, A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent, Propanc, 28 April 2011
WO/2011/044628, Allergy treatment using acid-treated aqueous whey protein extract, Dairy Australia and Women's and Children's Health Research Institute, 21 April 2011
WO/2011/041847, Chaperonin 10 variants, CBio Ltd, 14 April 2011
WO/2011/038451, Therapy and prevention of problem drinking, University of Sydney, 7 April 2011
WO/2011/032233, Novel omega conotoxin peptides, University of Queensland, 24 March 2011
WO/2011/032204, Treatment of neurological conditions, CSL Ltd, 24 March 2011
WO/2011/023584, Nano silver-zinc oxide composition, Polymers CRC, 3 March 2011
WO/2011/022772, Combination therapy for treating proliferative diseases, Bionomics, 3 March 2011
WO/2011/006204, Method of providing agents to the cochlea, University of New South Wales, 20 January 2011
WO/2011/003155, Biopolymer hybrid gel-depot delivery system, Polymers CRC, 13 January 2011
WO/2011/003129, Treatment of non-neuronal and non-myocardial cell, tissue and organ damage and associated pain with persistent sodium current blockers, Ozteo Pty Ltd, 13 January 2011
WO/2011/000054, Immuno-conjugates and methods for producing them, Avipep Pty Ltd, 6 January 2011
WO/2011/000053, Medicinal carbohydrates for treatment of respiratory conditions, Australian Biomedical Company Pty Ltd, 6 January 2011
WO/2010/143936, Composition and method for improving vascular health, Malaysian Palm Oil Board and Commonwealth Scientific and Industrial Research Organisation, 16 December 2010
WO/2010/139026, Therapeutic and diagnostic molecules, Centenary Institute of Cancer Medicine and Cell Biology, University Of Sydney, Medvet Science Pty Ltd and the Wenkart Foundation, 9 December 2010
WO/2010/139018, Novel strains of Helicobacter pylori and uses thereof, Ondek Pty Ltd, 9 December 2010
WO/2010/135781, Methods of treating diseases, Immunaid Pty Ltd, 2 December 2010
WO/2010/132959, Use of dynamin ring stabilizers, Children's Medical Research Institute and The General Hospital Corporation, 25 November 2010
WO/2010/132932, A temperature sensitive vaccine strain of Mycoplasma hyopneumoniae and uses thereof, Bioproperties Pty Ltd and University of Melbourne, 25 November 2010
WO/2010/127408, Dispersants in high-electrolyte solutions, Huntsman Corporation, 11 November 2010
WO/2010/127396, One or more of Vigna marina, Cocos nucifera L. or Terminalia catappa L. extracts for treating wounds, skin disorders and hair loss, Cimtech, 11 November 2010
WO/2010/125445, Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders, Pharmaxis, 4 November 2010
WO/2010/121328, A novel formulation of indomethacin, iCeutica Pty Ltd, 28 October 2010
WO/2010/118458, A multidose package, course and method of treatment for delivering predetermined multiple doses of a pharmaceutical, iNova Pharmaceuticals (Australia) Pty Ltd, 21 October 2010
WO/2010/115229, Immunogenic composition and uses thereof, University of Melbourne, 14 October 2010
WO/2010/111753, Compositions and methods for treatment of aortic fibrosis, Vectus Biosystems, 7 October 2010
WO/2010/105290, Humanised antibodies with anti-tumour activity, Cephalon Australia Pty Ltd, 23 September 2010
WO/2010/102337, Injectable biomaterials, University of Sydney, 16 September 2010
WO/2010/096868, Topical foam composition, Stiefel Research Australia Pty Ltd, 2 September 2010
WO/2010/094074, Pharmaceutical preparation and delivery system, Palmaya Pty Ltd, 26 August 2010
WO/2010/094068, Treatment of chronic inflammatory conditions, CSL Ltd and University of Melbourne, 26 August 2010
WO/2010/078300, Dual functioning ionic liquids and salts thereof, University of Alabama, Monash University, Queen's University Belfast, 8July 2010
WO/2010/071944, Quinazolinone compounds, Prana Biotechnology, 1 July 2010
WO/2010/071941, Plant extracts from acronychia species and their use, Ecobiotics, 1 July 2010
WO/2010/071924, Osteoarthritis treatment, University Of Melbourne, 1 July 2010
WO/2010/071923, Pain treatment, University of Melbourne, 1 July 2010
WO/2010/065433, Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate, Novartis and Medvet Science Pty Ltd, 10 June 2010
WO/2010/063080, Amphiphile prodrugs, Commonwealth Scientific and Industrial Research Organisation, 10 June 2010
WO/2010/063069, Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals, University of Melbourne, 10 June 2010
WO/2010/062264, Lipopeptide compounds and their use, UniQuest Pty Ltd, 3 June 2010
WO/2010/054437, Vaccine strains of Brachyspira hyodysenteriae, Spirogene Pty Ltd, 20 May 2010
WO/2010/046338, Composition for targeting dendritic cells, Domantis Ltd and Lipotek Pty Ltd, 29 April 2010
WO/2010/043000, S1P receptors modulators and their use thereof, Akaal Pharma, 22 April 2010
WO/2010/042997, Compositions and methods for treatment of kidney disorders, Vectus Biosystems, 22 April 2010
WO/2010/040188, Biodegradable polymer - bioactive moiety conjugates, Bionic Ear Institute, 15 April 2010
WO/2010/032141, Non-typeable Haemophilus influenzae vaccines and their uses, Hunter Immunology Ltd, 25 March 2010
WO/2010/028419, Prevention of psychotic disorders and/or treatment of psychotic symptoms, Orygen Research Centre, 18 March 2010
WO/2010/022463, Prevention, treatment and diagnosis of P. gingivalis infection, Oral Health Australia, 4 March 2010
WO/2010/022462, Mutant bacterial glycoproteins and uses thereof, University of Queensland, 4 March 2010
WO/2010/022452, Methods and compositions for treating and preventing malaria using an invasion ligand directed to a protease-resistant receptor, Walter and Eliza Hall Institute of Medical Research, 4 March 2010
WO/2010/020005, Therapeutic methods using adipose tissue-derived cell suspensions comprising adipocytes, Regeneus, 25 February 2010
WO/2010/017598, Anti-Il-12/Il-23 antibodies, Arana Therapeutics, 18 February 2010
WO/2010/015029, Compositions and methods for treating psychiatric disorders, Gosforth Centre (Holdings) Pty Ltd, 11 February 2010
WO/2010/015024, Plant anti-pathogen systems, Hexima, 11 February 2010
WO/2010/006377, Therapeutic agents, Nutripep Pty Ltd, 21 January 2010
WO/2010/004438, LM antibodies, functional fragments, LM-1 target antigen, and methods for making and using same, Patrys, 14 January 2010
WO/2010/003193, Peptide inhibitors of CD40L signaling and uses therefor, Phylogica, 14 January 2010
WO/2010/003191, Biocompatible material and uses thereof, University of Sydney, 14 January 2010
WO/2010/002867, Multivalent antihelminthic vaccine, Albert B. Sabin Vaccine Institute with QIMR Berghofer Medical Research Institute and George Washington University, 7 January 2010
WO/2010/000041, Anti-P2X7 peptides and epitopes, Biosceptre International, 7 January 2010
WO/2010/000011, The use of androgens for vascular regeneration and endothelial repair, Heart Research Institute, 7 January 2010
WO/2009/152551, Pharmaceutical formulation, Alphapharm Pty Ltd, 23 December 2009
WO/2009/143572, Methods of treating mammals with eustachian tube dysfunctions, University of Melbourne, 3 December 2009
WO/2009/143571, Antiviral salts, Biota, 3 December 2009
WO/2009/137890, Administrable compositions, University of Sydney, 19 November 2009
WO/2009/137889, Polymer microgel beads, University of Sydney, 19 November 2009
WO/2009/137888, Polymer microgel beads and preparative method thereof, University of Sydney, 19 November 2009
WO/2009/137881, Angiogenin-enriched milk fractions, Agriculture Victoria Services Pty Ltd and Murray Goulburn Co-Operative Co. Ltd, 19 November 2009
WO/2009/137880, Use of angiogenin or angiogenin agonists for treating diseases and disorders, Agriculture Victoria Services Pty Ltd and Murray Goulburn Co-Operative Co. Ltd, 19 November 2009
WO/2009/129578, Methods for radiolabelling synthetic polymers, Australian National University, 29 October 2009
WO/2009/129577, Methods for radiolabelling macromolecules, Australian National University, 29 October 2009
WO/2009/124353, Modified CPN10 and PRR signalling, CBio Ltd, 15 October 2009
WO/2009/118191, Therapy for vitiligo, Clinuvel Pharmaceuticals, 1 October 2009
WO/2009/111846, Mitochondrially delivered anti-cancer compounds, Cancure Ltd, 17 September 2009
WO/2009/108999, Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders, NAD Life Pty Ltd, 11 September 2009
WO/2009/105824, Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor, Mimetica Pty Ltd, 3 September 2009
WO/2009/105823, 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists, Mimetica, 3 September 2009
WO/2009/097735, Use of compounds extracted from Momordica charantia L. in the manufacture of medicaments for prevention and treatment of diabetes and obesity, Shanghai Institute Materia Medica, Chinese Academy of Sciences, Garvan Institute of Medical Research, 13 August 2009
WO/2009/097660, Patch production, University Of Queensland, 13 August 2009
WO/2009/097657, Method of producing progenitor cells from differentiated cells, Regenertech Pty Ltd, 13 August 2009
WO/2009/094730, Vaccine compositions, University of Newcastle, 6 August 2009
WO/2009/094717, A method of inducing tolerance to an allergen, Murdoch Childrens Research Institute, 6 August 2009
WO/2009/089593, Process for preparing nutritional, therapeutic or organoleptic products from crude glycerol, Bio Processing Australia Pty Ltd, 23 July 2009
WO/2009/086596, Method of producing a population of cells, University of Queensland, 16 July 2009
WO/2009/086591, Diagnostic and therapeutic methods for EFMR (epilepsy and mental retardation limited to females), Medvet Science Pty Ltd, 16 July 2009
WO/2009/079712, Coating method, University of Queensland, 2 July 2009
WO/2009/079683, Translocator protein ligands, University of Sydney, 2 July 2009
WO/2009/073930, Nutraceutical composition and methods of use, Dacy Tech Pty Ltd, 18 June 2009
WO/2009/073916, Improved treatment and prophylaxis, Mater Medical Research Institute, 18 June 2009
WO/2009/073911, Treatment and prophylaxis, Mater Medical Research Institute, 18 June 2009
WO/2009/070847, Compounds for therapy and diagnosis, Prana Biotechnology, 11 June 2009
WO/2009/070842, Protection of progenitor cells and regulation of their differentiation, Proteobioactives Pty Ltd, 11 June 2009
WO/2009/067734, Nanoemulsions, Commonwealth Scientific and Industrial Research Organisation, 4 June 2009
WO/2009/062254, Device and method for preparing microparticles, University of Queensland, 22 May 2009
WO/2009/061961, Use of Vitamin D receptor agonists and precursors to treat fibrosis, Salk Institute for Biological Studies and University of Sydney , 14 May 2009
WO/2009/059350, Anti-microbial polymers and their compositions, Recce, 14 May 2009
WO/2009/055859, Transdermal delivery system for hormones and steroids, Acrux, 7 May 2009
WO/2009/055854, Chimeric relaxin polypeptides comprising an A and B chain derived from different relaxin family peptides, Florey Institute of Neuroscience and Mental Health, 7 May 2009
WO/2009/052588, Cytokine muteins, CSL Ltd, 30 April 2009
WO/2009/052566, Anti-microbial composition, Wild Child, 30 April 2009
WO/2009/052555, Immunogenic protein Pas n 1 from Bahia grass pollen, University of Queensland and Queensland University of Technology, 30 April 2009
WO/2009/049350, Expression system for modulating an immune response, University of Queensland, 23 April 2009
WO/2009/046498, A method of transfection and compositions therefor, University of Melbourne, 16 April 2009
WO/2009/046497, Method of eliciting an immune response against pandemic influenza virus, CSL Ltd, 16 April 2009
WO/2009/043111, Composition and method for dermal regeneration, Ultraceuticals R & D Pty Ltd, 9 April 2009
WO/2009/043107, Treatment of neurological disorders, Velacor Therapeutics Pty Ltd, 9 April 2009
WO/2009/040507, Substituted benamidines as antibacterial agents, Prolysis Ltd, 2 April 2009
WO/2009/039567, Molecular delivery vesicle, University of Queensland, 2 April 2009
WO/2009/036510, Novel avian cytokines and genetic sequences encoding same, Commonwealth Scientific and Industrial Research Organisation and Australian Poultry CRC, 26 March 2009
WO/2009/033233, Novel P2X7 epitopes, Biosceptre International Ltd, 19 March 2009
WO/2009/031934, Method for producing vegetable cell sap concentrate and means for the production thereof, Solagran, 12 March 2009
WO/2009/029991, Agents with angiogenic and wound healing activity, Meat & Livestock Australia Ltd and Industrial Research Ltd, 12 March 2009
WO/2009/028965, Surgical hydrogel, Robinson Squidgel Ltd, University of Adelaide, University of Otago, 5 March 2009
WO/2009/026660, Dendritic cell marker and uses thereof, Walter and Eliza Hall Institute of Medical Research and Burnet Institute, 5 March 2009
WO/2009/021288, Improved gene silencing methods, Commonwealth Scientific and Industrial Research Organisation, 19 February 2009
WO/2009/021276, Cells genetically modified to comprise pancreatic islet glucokinase and uses thereof, University of Technology, Sydney, 19 February 2009
WO/2009/006700, Immunology treatment for biofilms, Oral Health Australia Pty Ltd, 15 January 2009
WO/2009/006699, Biofilm treatment, Oral Health Australia Pty Ltd, 15 January 2009
WO/2009/003226, Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration, Phovitreal Pty Ltd, 8 January 2009
WO/2008/154700, Compositions and uses thereof for the treatment of Acute Respiratory Distress Syndrome (ARDS) and clinical disorders associated with therewith, Phylogica, 24 December 2008
WO/2008/148174, Wound repair composition and method, Queensland University of Technology, 11 December 2008
WO/2008/148166, Clostridial toxin NetB, Australian Poultry CRC Pty Ltd , 11 December 2008
WO/2008/124872, Latent neural stem cell population, University of Queensland, 23 October 2008
WO/2008/119110, Treatment of obesity, Baker Medical Research Institute and Christian-Albrechts-Universitat zu Kiel, 9 October 2008
WO/2008/112192, EPHA3 antibodies for the treatment of solid tumors, Monash University, Ludwig Institute for Cancer Research and KaloBios Pharmaceuticals, 18 September 2008
WO/2008/109956, Treatment or prophylaxis of asthma, Hunter Immunology, 18 September 2008
WO/2008/106731, A target for breast cancer therapy and/or diagnosis, University of Queensland, 12 September 2008
WO/2008/106721, Compositions and methods for delivery of anti-cancer agents, University of Wollongong, 12 September 2008
WO/2008/095263, A dosage form containing two or more active pharmaceutical ingredients in different physical forms, Alphapharm Pty Ltd, 14 August 2008
WO/2008/095253, Treatment of ADHD, Gosforth Centre (Holdings) Pty Ltd, 14 August 2008
WO/2008/095221, Treatment of ADHD, Gosforth Centre (Holdings) Pty Ltd, 14 August 2008
WO/2008/093246, VEGF receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis, Vegenics Ltd, 7 August 2008
WO/2008/089521, Insulin sensitisers and methods of treatment, Verva Pharmaceuticals, 31 July 2008
WO/2008/083423, Spreading implement, Acrux, 17 July 2008
WO/2008/080194, Pain-relieving compositions and uses therefor, University of Queensland, 10 July 2008
WO/2008/064401, Improved peptide composition, Alzhyme Pty Ltd, 5 June 2008
WO/2008/061299, Method of treating diabetes, Garvan Institute of Medical Research, 29 May 2008
WO/2008/059616, Antibody recognizing C-domain of midkine, Cellmid, 22 May 2008
WO/2008/058323, Use of tropoelastin for repair or restoration of tissue, University of Sydney, 22 May 2008
WO/2008/055310, Process for the preparation of angiogenin, Murray Goulburn Co-Operative Co. Ltd and Agriculture Victoria Services Pty Ltd, 15 May 2008
WO/2008/052263, Delivery system for remote treatment of an animal, Veterinary Encapsulation Biosciences Pty Ltd, 8 May 2008
WO/2008/046135, Novel anxiolytic compounds, Bionomics, 24 April 2008
WO/2008/043157, Compositions and methods for modulating immune responses, University of Queensland, 17 April 2008
WO/2008/041909, A method of producing native components, such as growth factors or extracellular matrix proteins, through cell culturing of tissue samples for tissue repair, Norrfors SARL, 10 April 2008
WO/2008/040094, Particle formation, University of New South Wales, 10 April 2008
WO/2008/040060, VLP based vaccine delivery system, University of Queensland, 10 April 2008
WO/2008/037011, Polycyclic agents for the treatment of Respiratory Syncytial Virus infections, Biota, 3 April 2008
WO/2008/034180, Extracts derived from sugar cane and a process for their manufacture, Horizon Science Pty Ltd, 27 March 2008
WO/2008/034161, Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor, Phylogica, 27 March 2008
WO/2008/031172, Methods and compositions for promoting organ development, Kintan Pty Ltd, 20 March 2008
WO/2008/025099, Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions, Anthony Scammell, 6 March 2008
WO/2008/025095, Method of eliciting or inducing an immune response, CSL Ltd and University of Melbourne, 6 March 2008
WO/2008/025094, Method of treatment of photodermatoses, Clinuvel Pharmaceuticals, 6 March 2008
WO/2008/025073, Method of modulation of expression of Epidermal Growth Factor Receptor (EGF) involving miRNA, University of Western Australia, 6 March 2008
WO/2008/022401, Recombinant HCV E2 glycoprotein, Macfarlane Burnet Institute for Medical Research and Public Health, 28 February 2008
WO/2008/022391, Method for producing antibodies, G2 Inflammation Pty Ltd, 28 February 2008
WO/2008/017126, Treatment of pulmonary disease conditions, CSL Ltd, 14 February 2008
WO/2008/017125, Targeted polylysine dendrimer therapeutic agent, Starpharma, 14 February 2008
WO/2008/017122, Polylysine dendrimer contrast agent, Starpharma and Baker IDI Heart and Diabetes Institute, 14 February 2008
WO/2008/016314, Myostatin antagonists, Orico Ltd, 7 February 2008
WO/2008/014563, Methods and compositions for promoting activity of anti-cancer therapies, Oncology Research International Ltd, 7 February 2008
WO/2008/014555, Method of identifying CD4+CD25+ T cells activated to an antigen which express CD8, University of New South Wales, 7 February 2008
WO/2008/012695, Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells, EnGeneIC, 31 January 2008
WO/2008/012682, Methods and compositions for increasing tissue tropism of recombinant adenoviral vectors, Commonwealth Scientific and Industrial Research Organisation and Imugene Ltd, 31 January 2008
WO/2008/011664, Method of producing a population of cells, University of Queensland, 31 January 2008
WO/2008/008397, Fatty acid pharmaceutical foam, Stiefel Research Australia Pty Ltd, 17 January 2008
WO/2008/007224, Foamable suspension gel, Stiefel Research Australia Pty Ltd, 17 January 2008
WO/2008/003141, Therapeutic compounds, Fibrotech and University of Melbourne, 10 January 2008
WO/2008/000028, Porphyromonas gingivalis polypeptides useful in the prevention of periodontal disease, Oral Health Australia Pty Ltd, 3 January 2008
WO/2007/147217, Method of treatment of glioma brain tumour, Prana Biotechnology, 27 December 2007
WO/2007/145987, J-superfamily conotoxin peptides, University of Utah, University of Queensland, Max-Planck Society, 21 December 2007
WO/2007/143794, Formulation comprising whey protein and hydrolysates for improving muscle recovery, Murray Goulburn Co-Operative Co., 21 December 2007
WO/2007/137369, Medicinal compositions containing honey, Medihoney Pty Ltd, 6 December 2007
WO/2007/124541, Cox-2 inhibitor, Cambridge Scientific Pty Ltd , 8 November 2007
WO/2007/124540, Cytokine mediating composition, Cambridge Scientific Pty Ltd, 8 November 2007
WO/2007/124529, Modulation of T helper cell-mediated immune responses, Northern Sydney and Central Coast Area Health Service and University of Sydney, 8 November 2007
WO/2007/121522, Pestivirus species, NSW Department of Primary Industries, 1 November 2007
WO/2007/120533, Minigene expression cassette, Stanford University and Benitec Biopharma, 25 October 2007
WO/2007/118276, Method of treatment of Age-related Macular Degeneration (AMD), Prana Biotechnology, 25 October 2007
WO/2007/118270, Cyclised alpha-conotoxin peptides, University of Queensland, 25 October 2007
WO/2007/115376, Anti-angiogenic agents and methods of their use, University of Western Australia, KBC Research Foundation, Anna University , 18 October 2007
WO/2007/112475, A method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same, Alchemia, 11 October 2007
WO/2007/110631, Binding member for GM-CSF receptor, Medimmune and CSL Ltd, 4 October 2007
WO/2007/109851, Treatment of neurodegenerative diseases, Velacor Therapeutics Pty Ltd, 4 October 2007
WO/2007/107758, Antibacterial agents, Biota, 27 September 2007
WO/2007/106951, Antimicrobial protein, Agriculture Victoria Services Pty Ltd, 27 September 2007
WO/2007/106949, Tenocyte cell culturing method, University of Western Australia, 27 September 2007
WO/2007/106944, Contraceptive composition, Starpharma, 27 September 2007
WO/2007/106938, Method of treatment or prophylaxis inflammatory pain, University of Queensland, 27 September 2007
WO/2007/104070, Method and composition for treating allergic diseases, Wholesome Biopharm Pty Ltd, 20 September 2007
WO/2007/101232, Inhibition of JAK2 as a treatment of Pulmonary Arterial Hypertension, Cytopia, 7 September 2007
WO/2007/098557, Regulation of immune responses by modulation of the function of Antigen Presenting Cells, CBio, 7 September 2007
WO/2007/093177, Metallothionein-derived peptide fragments, University of Tasmania, 23 August 2007
WO/2007/090242, Fluoride composition and methods for dental mineralization, University of Melbourne, 16 August 2007
WO/2007/087689, A method of modulating cellular activity and agents for use therein, CRC for Asthma and Airways, 9 August 2007
WO/2007/087684, Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors, Bionomics, 9 August 2007
WO/2007/082331, Modified macromolecule, Starpharma, 26 July 2007
WO/2007/070985, Tiglien-3-one derivatives, QBiotics, 28 June 2007
WO/2007/070984, Spiroketals, Ecobiotics, 28 June 2007
WO/2007/070947, Antibacterial agents, Alchemia, 28 June 2007
WO/2007/068055, A method for preventing reduced feed intake in animals and treatment of disease conditions, Hancroft Pty Ltd, 21 June 2007
WO/2007/065226, VIP fragments and methods of use, Vectus Biosystems, 14 June 2007
WO/2007/062469, Methods and compositions for preventing and/or treating pancreatitis, Flinders Technologies Pty Ltd , 7 June 2007
WO/2007/056829, Multitargeting interfering RNAs having two active strands and methods for their design and use, Johnson & Johnson Research, 24 May 2007
WO/2007/056813, Pediculicide/ovicide composition, Wild Child, 24 May 2007
WO/2007/053904, Process to control particle size, Alphapharm Pty Ltd, 18 May 2007
WO/2007/048202, Methods and compositions for modulating wound repair, Women's & Children's Health Research Institute, University of Adelaide and Australian National University, 3 May 2007
WO/2007/048190, Macromolecular compounds having controlled stoichiometry, Starpharma, 3 May 2007
WO/2007/045027, Reduction of side effects from aromatase inhibitors used for treating breast cancer, Chavah Pty Ltd, 26 April 2007
WO/2007/045009, Microbicidal dendrimer composition delivery system, Starpharma, 26 April 2007
WO/2007/033419, Composition and method for inhibiting herpesviridae infections, Viratec Pty Ltd, 29 March 2007
WO/2007/028211, Composition of whey growth factor extract for reducing muscle inflammation, Murray Goulburn Co-Operative Co., 15 March 2007
WO/2007/028196, Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment, Alchemia, 13 March 2007
WO/2007/025343, Modified chaperonin 10, CBio, 8 March 2007
WO/2007/025333, Bacterial delivery of biologically active polypeptides, Commonwealth Scientific and Industrial Research Organisation, 8 March 2007
WO/2007/022287, Modified VEGF and PDGF with improved angiogenic properties, Ludwig Institute for Cancer Research, 22 February 2007
WO/2007/012133, Therapeutic protocols using hyaluronan, Alchemia, 1 February 2007
WO/2007/009166, Modulation of granulosa cell apoptosis, University of Adelaide, 25 January 2007
WO/2007/006095, Chaperonin 10-induced immunomodulation, CBio, 18 January 2007
WO/2007/006071, Improved process for the production of a radioactive aerosol, Cyclomedica Australia Pty Ltd, 18 January 2007
WO/2007/003010, Anticoagulation agent and uses thereof, Baker Medical Research Institute, 11 January 2007
WO/2006/135985, Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same, Walter and Eliza Hall Institute of Medical Research, 28 December 2006
WO/2006/135982, Ionic complexes, University of Melbourne, 28 December 2006
WO/2006/135978, Antiviral compounds and methods, Biotron, 28 December 2006
WO/2006/135965, Composition for treating skin lesions, Dynamiclear Pty Ltd, 28 December 2006
WO/2006/133519, Particles comprising a releasable dopant therein, Australian Nuclear Science and Technology Organisation, 21 December 2006
WO/2006/133518, Particles having hydrophobic material therein, Australian Nuclear Science And Technology Organisation, 21 December 2006
WO/2006/133506, A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof, Phosphagenics, 21 December 2006
WO/2006/130913, Dental mineralization, University of Melbourne, 14 December 2006
WO/2006/130904, Dried formulations of nanoparticle-coated capsules, University of South Australia, 14 December 2006
WO/2006/129161, Vitamin formulation, Stiefel Research Australia Pty Ltd , 7 December 2006
WO/2006/128259, Substances having body mass redistribution properties, Horizon Science Pty Ltd, 7 December 2006
WO/2006/125262, Methods and compositions for regulating biofilm development, Environmental Biotechnology CRC Pty Ltd, 30 November 2006
WO/2006/122345, Method and composition for use in preparation of a patient for surgery, Novapharm Research, 23 November 2006
WO/2006/116798, A method of forming an injectable radioactive composition of a carbon encapsulated radioactive particulate, Australian National University, 9 November 2006
WO/2006/110491, Complementary compositions to reduce blood glucose levels and treat diabetes, Astrum Therapeutics Pty Ltd, 19 October 2006
WO/2006/105615, Buccal delivery system, Ozpharma Pty Ltd, 12 October 2006
WO/2006/105597, Variants of Hepatitis B Virus with resistance to anti-viral nucleoside agents and applications thereof, Melbourne Health, St. Vincent's Hospital Melbourne and Austin Health, 12 October 2006
WO/2006/096931, Renal repair and regeneration, University Of Queensland and Monash University, 21 September 2006
WO/2006/096914, A topical analgesic composition, Animal Ethics Pty Ltd, 21 September 2006
WO/2006/096905, Control of sucking lice, Microbial Products Pty Ltd, 21 September 2006
WO/2006/094357, Flavonoid compounds and uses thereof, Howard Florey Institute of Experimental Physiology and Medicine, and Neuprotect Pty Ltd, 14 September 2006
WO/2006/094347, Bicyclic nucleosides and nucleotides as therapeutic agents, Biota, 14 September 2006
WO/2006/089348, Anti-microbial agent, Kayban Pty Ltd, 31 August 2006
WO/2006/086821, Antisense modulation of integrin α4 expression, Antisense Therapeutics, 24 August 2006
WO/2006/084339, Layered nanoparticles, Australian Nuclear Science & Technology Organisation, 17 August 2006
WO/2006/084334, Analgesic and anti-inflammatory composition, Cambridge Scientific Pty Ltd, 17 August 2006
WO/2006/081620, CD4+ CD25+ T-cells activated to a specific antigen, University of New South Wales, 10 August 2006
WO/2006/069422, Method and means for improving bowel health, Commonwealth Scientific and Industrial Research Organisation and Biogemma, 6 July 2006
WO/2006/066361, Method of treatment or prophylaxis, University of Queensland, 29 June 2006
WO/2006/066354, Formula ions and treatments for well-being, Dolphst Pty Ltd, 29 June 2006
WO/2006/066323, Formulations and treatments for trichology, Dolphst Pty Ltd, 29 June 2006
WO/2006/066317, Controlled release of biological entities, Australian Nuclear Science & Technology Organisation, 29 June 2006
WO/2006/063415, Regulation of metalloprotease cleavage of cell surface proteins, Monash University and Memorial Sloan Kettering Cancer Center, 22 June 2006
WO/2006/062087, Composition for treating or preventing myocardial disorder or heart failure, Cellmid and Nagoya University, 15 June 2006
WO/2006/060871, Binding partners of antibodies specific for dendritic cell antigens, Mater Medical Research Institute, 15 June 2006
WO/2006/060853, Treatment for cancer, University of New South Wales, 15 June 2006
WO/2006/056027, Human Cytomegalovirus immunotherapy, QIMR Berghofer Medical Research Institute, 1 June 2006
WO/2006/056013, Stabilized calcium phosphate complexes, University Of Melbourne, 1 June 2006
WO/2006/047830, Arthrospira-based compositions and uses thereof, Biovite Australia Pty Ltd, 11 May 2006
WO/2006/045152, Improved tabletting process, Mayne Pharma International Pty Ltd, 4 May 2006
WO/2006/037188, Compositions and methods for inducing melanogenesis in a subject, Clinuvel Pharmaceuticals, 13 April 2006
WO/2006/036074, Myostatin isoform, Orico Ltd, 6 April 2006
WO/2006/034545, Variants of Hepatitis B Virus with resistance to anti-viral nucleoside agents and applications thereof, Melbourne Health and Fundación para la Investifación y Educación en SIDA, 6 April 2006
WO/2006/032104, Antigenic complex for the diagnosis and treatment of Porphyromonas gingivalis infection, University of Melbourne, 30 March 2006
WO/2006/032085, Substituted chroman derivatives, medicaments and use in therapy, Novogen, 30 March 2006
WO/2006/024100, New polymorphic form of inulin and uses thereof, Vaxine Pty Ltd, 9 March 2006
WO/2006/024092, VEGF inhibition, University of New South Wales, 9 March 2006
WO/2006/021894, Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells, EnGeneIC, 2 March 2006
WO/2006/018743, Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder, Biolog Health Solutions Pty Ltd and Tracey Seipel, 23 February 2006
WO/2006/017914, Methods and compositions for treatment of hematologic cancers, Viralytics, 23 February 2006
WO/2006/017896, Metabolism-modulating agents and uses therefor, University of Queensland, 23 February 2006
WO/2006/017895, Oral killed vaccines and method for providing same, Hunter Immunology Pty Ltd, 23 February 2006
WO/2006/015445, Bacterial delivery system, Barry Marshall, 16 February 2006
WO/2006/012688, A method of treating cancer comprising a VEGF-B antagonist, CSL Ltd, 9 February 2006
WO/2006/012667, Methods of inducing melanogenesis in a subject, Clinuvel Pharmaceuticals, 9 February 2006
WO/2006/010221, A colour compensating system, Blonde Holdings Pty Ltd, 2 February 2006
WO/2006/007667, Therapeutic and diagnostic agents, Walter and Eliza Hall Institute of Medical Research, 26 January 2006
WO/2006/002493, An echinacea formulation, Mediherb Holdings Ltd, 12 January 2006
WO/2005/120545, Compositions and methods for treatment of cardiovascular disease, Vectus Biosystems, 22 December 2005
WO/2005/117608, Natural sweetener, Horizon Science Pty Ltd, 15 December 2005
WO/2005/115430, Treatment of inflammatory airway disease, GroPep, 8 December 2005
WO/2005/115345, Oral therapeutic compound delivery system, Imaginot Pty Ltd , 8 December 2005
WO/2005/113004, Small molecule inhibitors for MRP1 and other multidrug transporters, Cleveland Clinic and University of New South Wales, 1 December 2005
WO/2005/108430, Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent, Scancell Ltd, 17 November 2005
WO/2005/105132, Methods for preventing or treating bone disorders, Metabolic Pharmaceuticals, 10 November 2005
WO/2005/100374, Therapeutic heparins and their binding to interleukins 4 and 5, and PECAM-1, Curtin University of Technology, 27 October 2005
WO/2005/099746, Method for modulating appetite, St Vincent's Hospital Sydney, 27 October 2005
WO/2005/097094, Antimicrobial compositions and methods for their use, Dermcare-Vet Pty Ltd, 20 October 2005
WO/2005/094162, Culture and use of cells that secrete liver secretory factors, Fac8Cell Pty Ltd, 13 October 2005
WO/2005/090388, Alpha helical mimics, their uses and methods for their production, University of Queensland, 29 September 2005
WO/2005/089778, Biodegradable polyurethane and polyurethane ureas, Commonwealth Scientific and Industrial Research Organisation, 29 September 2005
WO/2005/087931, Modified oncolytic viruses, Viralytics, 22 September 2005
WO/2005/087926, Multiple promoter expression cassettes for simultaneous delivery of RNAi agents, Benitec Biopharma, 22 September 2005
WO/2005/087808, Growth factor binding constructs materials and methods, Ludwig Institute for Cancer Research, 22 September 2005
WO/2005/087177, Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same, Ludwig Institute for Cancer Research, 22 September 2005
WO/2005/084678, Alkaloid formulations, Vital Health Sciences Pty Ltd, 15 September 2005
WO/2005/082894, Cell targeting conjugates, Peter MacCallum Cancer Centre, 9 September 2005
WO/2005/081854, EGF receptor epitope peptides and uses thereof, Commonwealth Scientific and Industrial Research Organization, Ludwig Institute for Cancer Research and Massachusetts Institute of Technology, 9 September 2005
WO/2005/079854, Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells, EnGeneIC, 1 September 2005
WO/2005/077299, Isolated plasma and method for hyperimmunisation and plasma collection, Plasma Ventures Pty Ltd, 25 August 2005
WO/2005/067959, Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion, CBio, 28 July 2005
WO/2005/063991, Live genetically attenuated malaria vaccine, Seattle Biomedical Research Institute and Heidelberg University, 14 July 2005
WO/2005/061513, Polycyclic agents for the treatment of Respiratory Syncytial Virus infections, Biota, 7 July 2005
WO/2005/060739, Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5aR, G2 Inflammation Pty Ltd, 7 July 2005
WO/2005/058344, Antimicrobial composition, University of Melbourne, 30 June 2005
WO/2005/058319, Methods and compositions, CNSBio Pty Ltd, 30 June 2005
WO/2005/056749, Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells, EnGeneIC, 23 June 2005
WO/2005/049635, Human monoclonal antibody having fat-reducing effect, Peter Vollmers, 2 June 2005
WO/2005/048998, GI tract delivery systems, Commonwealth Scientific and Industrial Research Organisation, 2 June 2005
WO/2005/048967, A method of inducing melanogenesis in humans with MC1R variant alleles, Clinuvel Pharmaceuticals, 2 June 2005
WO/2005/047332, Adenocarcinoma specific antibody SAM-6, and uses thereof, Patrys, 26 May 2005
WO/2005/044874, Method of manufacture of polyacrolein, Chemeq, 19 May 2005
WO/2005/042733, HBV variants detection and application, Melbourne Health, Austin Health, Southern Health, Bayside Health and St. Vincent's Hospital Melbourne, 12 May 2005
WO/2005/040816, Method of therapy, Immunaid Pty Ltd, 6 May 2005
WO/2005/037308, Methods and agents for the treatment of cancer, Inter-K Pty Ltd, 28 April 2005
WO/2005/037293, Immunomodulating compositions and uses therefor, Griffith University and Monash University, 28 April 2005
WO/2005/035548, The modulation of hyaluronan synthesis and degradation in the treatment of disease, Alchemia, 21 April 2005
WO/2005/034871, Methods for treating diseases and conditions with inverse agonists, Invion, 21 April 2005
WO/2005/033077, Sequence selective pyrrole and imidazole polyamide metallocomplexes, University of Western Sydney, 14 April 2005
WO/2005/032578, Therapeutic method, Monash University, 14 April 2005
WO/2005/030229, Probiotic storage and delivery, Commonwealth Scientific and Industrial Research Organisation, 7 April 2005
WO/2005/030205, Ocular solutions containing a macrolide antibiotic and/or mycophenolic acid, Advanced Ocular Systems, 7 April 2005
WO/2005/025621, Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness, QRxPharma, 24 March 2005
WO/2005/025602, Methods for identifying modulators of protein kinase c-epsilon, Garvan Institute of Medical Research, 24 March 2005
WO/2005/020997, Compositions for veterinary and medical applications, Australian Biomedical Company Pty Ltd, 10 March 2005
WO/2005/019440, Methods for enhancing embryo viability, Northern Sydney and Central Coast Area Health Service, 3 March 2005
WO/2005/018665, Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including Plasmodium spp, McGill University and QIMR Berghofer Medical Research Institute, 3 March 2005
WO/2005/012508, Skin regeneration system, Queensland University of Technology, 10 February 2005
WO/2005/012251, Therapeutic agent for chronic obstructive pulmonary disease and method of treatment for Chronic Obstructive Pulmonary Disease with the same, Mariposa Health, 10 February 2005
WO/2005/011813, Treatment of ocular disease, Gholam Peyman , 10 February 2005
WO/2005/011724, A method of producing an anticoagulation effect, Cryptome Pharmaceuticals, 10 February 2005
WO/2005/007188, Methods and compositions for controlling ectoparasites, Hatchtech Pty Ltd, 27 January 2005
WO/2004/113507, Pharmaceutically compatible method for purifying intact bacterial minicells, EnGeneIC, 29 December 2004
WO/2004/110475, Connective tissue derived polypeptides, Proteobioactives Pty Ltd, 23 December 2004
WO/2004/092387, Viral vectors expressing fusion of viral large envelope protein and protein of interest, Hepgenics Pty Ltd, 28 October 2004
WO/2004/092223, Cross-linked polysaccharide composition, Ultraceuticals R & D Pty Ltd, 28 October 2004
WO/2004/088322, Multiplex screening for Lysosomal Storage Disorders (LSDs), Women's and Children's Hospital, 14 October 2004
WO/2004/078922, Modulation of growth hormone receptor expression and insulin-like growth factor expression, Antisense Pharmaceuticals, 16 September 2004
WO/2004/078210, Preventive for adhesion following abdominal surgery, Cellmid, 16 September 2004
WO/2004/078209, Composition and method for the treatment and prevention of enteric bacterial infections, Immuron, 16 September 2004
WO/2004/073739, A method of diagnosis and treatment, Medvet Science Pty Ltd, 2 September 2004
WO/2004/072284, Modulation of Insulin like Growth Factor I receptor expression, Antisense Therapeutics, 26 August 2004
WO/2004/071479, Film foaming hydroalcoholic foam, Connetics Australia Pty Ltd, 26 August 2004
WO/2004/069871, Growth factor complexes and modulation of cell migration and growth, Queensland University of Technology, 19 August 2004
WO/2004/064833, Clindamycin phosphate foam, Connetics Australia Pty Ltd, 5 August 2004
WO/2004/064822, Method of inhibiting prostate cancer cell proliferation, Kieran Scott, Garry Graham and Qihan Dong, 5 August 2004
WO/2004/054613, A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis, Viralytics, 1 July 2004
WO/2004/050690, Novel χ-Conotoxin peptides - I, Xenome, 17 June 2004
WO/2004/050688, Novel χ-Conotoxin peptides - II, Xenome, 17 June 2004
WO/2004/050056, Cochlear implant drug delivery device, Cochlear, 17 June 2004
WO/2004/043480, Intraocular administration of Cyclosporin A for the treatment of macular degeneration, retinopathy or retinitis pigmentosa, Gholam Peyman, 27 May 2004
WO/2004/042079, Induction of the mitochondrial permeability transition, University of New South Wales, 21 May 2004
WO/2004/041300, Chaperonin 10 immunosuppression, CBio, 21 May 2004
WO/2004/039793, Aminated isoflavonoid derivatives and uses thereof, Novogen, 13 May 2004
WO/2004/035079, Treatment of osteoarthritis, University of Queensland, 29 April 2004
WO/2004/035078, Treatment of inflammatory bowel disease, University of Queensland, 29 April 2004
WO/2004/035062, Carbohydrate based anti-bacterials, Alchemia, 29 April 2004
WO/2004/032940, Classes of compounds that interact with GPCRs, Alchemia, 22 April 2004
WO/2004/031161, Neurologically-active compounds, Prana Biotechnology, 15 April 2004
WO/2004/030662, Combination chemotherapy compositions and methods, Novogen, 15 April 2004
WO/2004/024773, Methods for regulating cancer, Queen Elizabeth Hospital Research Foundation, 25 March 2004
WO/2004/022572, Compounds that interact with kinases, Alchemia, 18 March 2004
WO/2004/016101, Compositions comprising dietary fat complexer and methods for their use, Catherine Jen and Joseph Artiss, 26 February 2004
WO/2004/014957, Novel immunogenic lipopeptides comprising T-helper and Cytotoxic T Lymphocyte (CTL) epitopes, QIMR Berghofer Medical Research Institute, 19 February 2004
WO/2004/014956, Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes, QIMR Berghofer Medical Research Institute, 19 February 2004
WO/2004/014432, Carrier, Vital Health Sciences Pty Ltd, 19 February 2004
WO/2004/014159, Method of lowering glycaemic index of foods, Queen Bioactives Pty Ltd , 19 February 2004
WO/2004/011026, Immunogenic compositions and diagnostic and therapeutic uses thereof, Walter and Eliza Hall Institute of Medical Research, 5 February 2004
WO/2004/009773, Methods and compositions for activating or inhibiting VEGF-D and VEGF-C, Ludwig Institute for Cancer Research, 29 January 2004
WO/2004/009227, Biodegradable polyurethane/urea compositions, Commonwealth Scientific and Industrial Research Organisation, 29 January 2004
WO/2004/009035, Compositions and products containing enantiomeric equol, and methods for their making, Childrens Hospital Medical Center and Australian Health & Nutrition, 29 January 2004
WO/2004/008887, Fruit and/or vegetable derived composition, Phoenix Eagle Company Pty Ltd, 29 January 2004
WO/2004/007543, Altered Insulin-like Growth Factor binding proteins, University of Adelaide, 22 January 2004
WO/2004/007461, 8-hydroxy quinoline derivatives, Prana Biotechnology, 22 January 2004
WO/2004/005351, Neoplasm specific antibodies and uses thereof, Patrys, 15 January 2004
WO/2004/003161, Immunogenic Mycoplasma hyopneumoniae polypeptides, University of Iowa and NSW Department of Agriculture, 8 January 2004
WO/2004/001022, Probiotic Propionibacterium jensenii 702, University of Newcastle, 31 December 2003
WO/2004/000263, Transdermal delivery rate control using amorphous pharmaceutical compositions, Acrux, 31 December 2003
WO/2003/104203, Therapeutic molecules and methods-1, Cortical Pty Ltd, 18 December 2003
WO/2003/099811, Kinase inhibitors, Cytopia, 4 December 2003
WO/2003/095421, Amino acid analogues, Mimotopes Pty Ltd and Baker Medical Research Institute, 20 November 2003
WO/2003/086448, Use of c5a receptor antagonist in the treatment of fibrosis, Promics Pty Ltd, 23 October 2003
WO/2003/082914, Prothrombin activating protein, University of Queensland, 9 October 2003
WO/2003/075670, Treatment and prevention of inflammatory disorders, Monsanto,18 September 2003
WO/2003/072114, Vascular therapeutics, University of New South Wales, 4 September 2003
WO/2003/066841, Viral variants with altered susceptibility to nucleoside analogs and uses thereof, Melbourne Health, Austin and Repatriation Medical Centre and Southern Health , 14 August 2003
WO/2003/062279, Nutraceuticals for the treatment, protection and restoration of connective tissues, Institute of Nutraceutical Research Pty Ltd, 31 July 2003
WO/2003/062278, Monoclonal antibodies against extracellular loops of C5aR, G2 Therapies, 31 July 2003
WO/2003/061767, Methods and compositions for the treatment of asthma and related disorders, Atopic Pty Ltd, 31 July 2003
WO/2003/055514, Compositions comprising immunoreactive reagents and saponins, and methods of use thereof, CSL Ltd, 10 July 2003
WO/2003/049730, Treatment of statin side effects using uridine derivatives, Magral Ltd, 19 June 2003
WO/2003/040138, Dimeric compounds and their use as anti-viral agents, Biota, 15 May 2003
WO/2003/040137, Dimeric compounds and their use as anti-viral agents, Biota, 15 May 2003
WO/2003/040136, Dimeric compounds and their use as anti-viral agents, Biota, 15 May 2003
WO/2003/039564, Selective targeting of apoptotic cells, University of New South Wales, 15 May 2003
WO/2003/033528, Cyclic peptides as G-Protein Coupled Receptor antagonists, University of Queensland, 24 April 2003
WO/2003/030930, Human 3 relaxin, Florey Institute of Neuroscience and Mental Health, 17 April 2003
WO/2003/026681, Inactivation of papillomavirus, Jenny McCloskey, 3 April 2003
WO/2003/025009, Recombinant allergen with reduced IgE binding but undiminished T-cell antigenicity, University of Melbourne, 27 March 2003
WO/2003/020762, Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions, Biosceptre International, 13 March 2003
WO/2003/018781, Regulation of cytotrophoblast cell differentiation and cell migration, University of Adelaide, 6 March 2003
WO/2003/018069, Preparation and diabetic use of gibberellins, Australian Biomedical Company Pty Ltd, 6 March 2003
WO/2003/014122, Derivatives of morphine-like opioid compounds, Polychip Pharmaceuticals Pty Ltd and Monash University, 20 February 2003
WO/2003/011303, Dermal therapy using phosphate derivatives of electron transfer agents, Vital Health Sciences Pty Ltd, 13 February 2003
WO/2003/006691, Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells, Johnson & Johnson Research, 23 January 2003
WO/2003/006073, A composition and uses therefor for combating hangover, Penam Investments Pty Ltd, 23 January 2003
WO/2003/004684, Nucleic acids encoding a recombinant 250 kDa antigen from sporozoites/merozoites of Eimeria maxima and their uses, David Witcombe, Nicholas Smith and Michael Wallach, 16 January 2003
WO/2003/004644, Delivery of dsRNA to arthropods, Commonwealth Scientific and Industrial Research Organisation, 16 January 2003
WO/2003/004056, Method for treating Multiple Myeloma, Pacmab Pty Ltd, 16 January 2003
WO/2003/002594, Hypoglycaemic peptides and methods of use thereof, International Diabetes Institute and Monash University, 9 January 2003
WO/2003/002545, Peptoid compounds, University of Wollongong, 9 January 2003
WO/2003/000899, Mutant forms of EtxB and CtxB and their use as carriers, University of Bristol, 3 January 2003
WO/2003/000736, Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin, Agen Biomedical, 3 January 2003
WO/2002/102999, Attenuated circovirus, University of Melbourne, 27 December 2002
WO/2002/102789, Antimicrobial and radioprotective compounds, BioDiem, 27 December 2002
WO/2002/100445, Treatment and composition for wound healing, University of Sydney, 19 December 2002
WO/2002/098921, Recombinant antibodies against Infectious Bursal Disease Virus (IBDV), Commonwealth Scientific and Industrial Research Organisation, 12 December 2002
WO/2002/097094, Bcl-2-Modifying Factor (BMF) sequences and their use in modulating apoptosis, Walter and Eliza Hall Institute of Medical Research, 5 December 2002
WO/2002/097067, A method of purification of cells, Walter and Eliza Hall Institute of Medical Research, 5 December 2002
WO/2002/096949, Antigen targeting, QIMR Berghofer Medical Research Institute, 5 December 2002
WO/2002/094204, Dental restorative materials, University of Melbourne, 28 November 2002
WO/2002/092126, Binding member which binds to both Lewis y and Lewis b haptens, and its use for treating cancer, Scancell, 21 November 2002
WO/2002/089587, Methods and compositions for controlling pests, Bioprospect and University of Western Sydney, 14 November 2002
WO/2002/088184, A molecular marker, Murdoch Children's Research Institute, 7 November 2002
WO/2002/083181, Novel compositions and uses therefor, University of Queensland, 24 October 2002
WO/2002/079299, Agent for the prevention and treatment of sexually transmitted diseases - I, Starpharma, 10 October 2002
WO/2002/079236, Alpha conotoxin peptides with analgesic properties, Bruce Livett, Zeinab Khalil, Kenwyn Gayler and John Down, 10 October 2002
WO/2002/077033, Antibodies against cancer, Austin Research Institute, 3 October 2002
WO/2002/074305, Use of a substantially cell membrane impermeable compound for treating arthritis, University of New South Wales, 26 September 2002
WO/2002/062351, A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis, Royal Alexandra Hospital for Children, 15 August 2002
WO/2002/061081, A novel gene BNO1 mapping to chromosome 16q24.3, Bionomics, 8 August 2002
WO/2002/060950, FLT4 (FEGFR-3) as a target for tumor imaging and anti-tumor therapy, Ludwig Institute for Cancer Research, 8 August 2002
WO/2002/060927, Protein kinase signalling, Cytopia, 8 August 2002
WO/2002/057306, Antibodies to non-functional P2X7 receptor diagnosis and treatment of cancers and other conditions, BioScceptre International Ltd, 25 July 2002
WO/2002/057299, VEGFR-3 binding peptides and their use for inhibiting angiogenesis, Ludwig Institute for Cancer Research, 25 July 2002
WO/2002/055547, sRFP and peptide motifs that interact with sFRP and methods of their use, US Department of Health and Human Services and St Vincents Institute of Medical Research, 18 July 2002
WO/2002/053572, Delivery systems, Alchemia, 11 July 2002
WO/2002/051993, MAP kinase integrin-binding domain, University of Newcastle, 4 July 2002
WO/2002/050096, Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus, Bionomics, 27 June 2002
WO/2002/050089, Method for purification of lactose, University of Western Sydney, Dairy Research and Development Corporation, Commonwealth Scientific and Industrial Research Organisation and Australian Food Industry Science Centre, 27 June 2002
WO/2002/050045, Antiviral agents, Biota, 27 June 2002
WO/2002/044216, Probes for identifying cancer-specific antigens, Cancerprobe Pty Ltd, 6 June 2002
WO/2002/041901, Treatment of osteoporosis, Arthropharm Pty Ltd , 30 May 2002
WO/2002/040033, Formulation containing phosphate derivatives of electron transfer agents, Vital Health Sciences Pty Ltd, 23 May 2002
WO/2002/038594, Novel therapeutic compositions for treating infection by Lawsonia spp, Agriculture Victoria Services Pty Ltd, Australian Pork Ltd and Pfizer, 16 May 2002
WO/2002/036784, Transgenic animals for analysing cyp3a4 cytochrome p450 gene regulation, University of Sydney, 10 May 2002
WO/2002/034900, Dipeptidyl peptidases, University of Sydney, 2 May 2002
WO/2002/034299, Inorganic low density radionuclide coated particles, Sirtex Medical, 2 May 2002
WO/2002/034298, Low density radionuclide-containing particulate material, Sirtex Medical, 2 May 2002
WO/2002/024219, Growth factor complex, Queensland University of Technology, 28 March 2002
WO/2002/022164, Composition comprising immunogenic microparticles, Austin Research Institute, 21 March 2002
WO/2002/017971, Slow release pharmaceutical preparation and method of administering same, Palmaya Pty Ltd, 7 March 2002
WO/2002/015914, Vascularised tissue graft, Bernard O'Brien Institute of Microsurgery, 28 February 2002
WO/2002/011743, Treatment of prostate cancer, Peplin Biotech, 14 February 2002
WO/2002/010341, Microsporidia isolate, University of Technology Sydney, 7 February 2002
WO/2002/007682, Methods for treating atopic disorders, John Vyden, 31 January 2002
WO/2002/005852, Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease, Alchemia, 24 January 2002
WO/2002/005828, Compositions and methods for the treatment of skin damage, Gropep, 24 January 2002
WO/2002/000245, Neurotoxic oligomers, Prana Biotechnology and Massachusetts General Hospital, 3 January 2002
WO/2001/097836, Compositions and methods for treatment of candidiasis, Candivax Pty Ltd, 27 December 2001
WO/2001/094559, Hepatitis B Virus DNA polymerase and surface antigen variants and methods of using same, Melbourne Health, University of Hong Kong, Austin and Repatriation Medical Centre and Central Sydney Area Health Service, 13 December 2001
WO/2001/093912, Vaccine, Austin Research Institute and University of Melbourne , 13 December 2001
WO/2001/093885, Therapeutic agents - II, Peplin Biotech, 13 December 2001
WO/2001/090197, Synthetic peptides and uses therefore, Australian National University, 29 November 2001
WO/2001/088097, Immune potentiating compositions, Monash University and Griffith University, 22 November 2001
WO/2001/087332, Compositions and methods for treatment of mucosal infections, Hunter Immunology Ltd, 22 November 2001
WO/2001/083530, Porphyromonas gingivalis recombinant proteins and truncations, CSL Ltd, 8 November 2001
WO/2001/083519, Antigenic peptide fragments of VAPA protein, and uses thereof, University of South Australia, Medvet Science Pty Ltd and Rural Industries Research and Development Corporation, 8 November 2001
WO/2001/081928, Diagnostic assay and method of treatment involving Macrophage Inhibitory Cytokine -1 (MIC-1), St Vincent's Hospital Sydney, 1 November 2001
WO/2001/076594, Antimicrobial coatings, University of New South Wales, 18 October 2001
WO/2001/073078, A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide, Macfarlane Burnet Institute for Medical Research and Public Health, 4 October 2001
WO/2001/072310, Pharmaceutical gel composition, Chiltern Pharmaceuticals Pty Ltd , 4 October 2001
WO/2001/070755, Methods of synthesis and use of radiolabelled platinum chemotherapeutic agents, Australian Nuclear Science & Technology Organisation , 27 September 2001
WO/2001/070234, Anaesthetic composition, Jurox Pty Ltd, 27 September 2001
WO/2001/062942, Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators, Ludwig Institute for Cancer Research, 30 August 2001
WO/2001/062281, PAI-2 conjugates for the treatment and imaging of cancer, University of Wollongong, Medical Scitec Australia Pty Ltd and Biotech Australia Pty Ltd, 30 August 2001
WO/2001/062232, Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use, Australian Nuclear Science & Technology Organisation, 30 August 2001
WO/2001/060979, Pancreatic islet cell growth factors, Walter and Eliza Hall Institute of Medical Research , 23 August 2001
WO/2001/055182, Proteins comprising conserved regions of Neisseria meningitidis surface antigen NhhA, University of Queensland, 2 August 2001
WO/2001/052871, Preparation and xenotransplantation of porcine islets, Diatranz, 26 July 2001
WO/2001/052844, Brain, spinal, and nerve injury treatment, Eustralis Pharmaceuticals, 26 July 2001
WO/2001/047961, P. gingivalis antigenic composition, CSL Ltd, 5 July 2001
WO/2001/047492, Improved pharmaceutical compositions for poorly soluble drugs, F H Faulding & Co., 5 July 2001
WO/2001/042301, Interferon-alpha induced gene, Pharma Pacific Pty Ltd, 14 June 2001
WO/2001/038374, Tumour suppressor factor, University of Western Australia, 31 May 2001
WO/2001/037866, A method of treating a malignancy in a subject and a pharmaceutical composition for use in same, Viralytics, 31 May 2001
WO/2001/033977, Product and method for control of obesity, Metabolic Pharmaceuticals, 17 May 2001
WO/2001/029198, Polypeptide fragments comprising c-terminal portion of Helicobacter catalase, Chris Doidge, Elizabeth Webb, Linda Rothel, Philip Sutton and Stuart Hazell, 26 April 2001
WO/2001/029079, Immuno-interactive fragments of the αC subunit of inhibin, Prince Henry's Institute of Medical Research, 26 April 2001
WO/2001/027157, A biologically active complex of NR6 and cardiotrophin-like-cytokine, Amrad, 19 April 2001
WO/2001/027132, Estradiol conjugates and uses thereof, University of Melbourne , 19 April 2001
WO/2001/021172, Anti-cancer nitro- and thia-fatty acids, Women's and Children's Hospital Adelaide , 29 March 2001
WO/2001/019960, Recombinant microorganisms expressing an oligosaccharide receptor mimic, Women's and Children's Hospital and Luminis Pty Ltd, 22 March 2001
WO/2001/019866, Dipeptidyl peptidases, University of Sydney, 22 March 2001
WO/2001/019822, Antiviral agents, Biota, 22 March 2001
WO/2001/017530, Iron chelators and uses thereof, Heart Research Institute and University of Queensland , 15 March 2001
WO/2001/016172, Vaccine antigens of Moraxella, Commonwealth Scientific and Industrial Research Organisation and University of Melbourne, 8 March 2001
WO/2001/012179, Ophthalmic fluid, Planned Products Pty Ltd, 22 February 2001
WO/2001/007442, Beta-amyloid peptide inhibitors, Biomolecular Research Institute and University of Melbourne, 1 February 2001
WO/2001/005410, Neurotropic virus transport, Westmead Hospital and University of Sydney , 25 January 2001
WO/2001/002008, Control of acidosis, University of New England, 11 January 2001
WO/2000/078341, A method for the prophylaxis and/or treatment of medical disorders, Murdoch Children's Research Institute , 28 December 2000
WO/2000/072875, A method of prophylaxis and treatment and agents useful for same, University of Sydney, 7 December 2000
WO/2000/069906, Lawsonia derived gene and related hemolysin polypeptides, peptides and proteins and their uses, Pfizer, Agriculture Victoria Services Pty Ltd and Australian Pork Ltd, 23 November 2000
WO/2000/069451, A method of identifying therapeutic compounds for a treatment of hepatic disorders, University of Newcastle, 23 November 2000
WO/2000/066576, Isoflavone metabolites, G.J. Consultants Pty Ltd, 9 November 2000
WO/2000/066172, Non-aqueous liquid shampoo composition, Soltec Research Pty Ltd, 9 November 2000
WO/2000/061758, Viral variants, Melbourne Health, 19 October 2000
WO/2000/061607, Separation of plasma components, Gradipore, 19 October 2000
WO/2000/059520, Herbal compositions and uses for the treatment of allergic reactions, Guorang Hu , 12 October 2000
WO/2000/058511, Screening and therapy for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3), Ludwig Institute for Cancer Research, Helsinki University and University of Pittsburgh, 5 October 2000
WO/2000/056145, Organ arrest, protection and preservation, James Cook University, 28 September 2000
WO/2000/052714, Heating of magnetic material by hysteresis effects, Sirtex Medical, 8 September 2000
WO/2000/052156, Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene, Commonwealth Scientific and Industrial Research Organisation, 8 September 2000
WO/2000/052041, Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with Porphyromonas gingivalis, University of Melbourne, CSL Ltd and Victorian Dairy Industry Authority , 8 September 2000
WO/2000/048630, Immunogenic complexes and methods relating thereto, CSL Ltd, 24 August 2000
WO/2000/047620, Cytokine-binding domain, Medvet Science Pty Ltd, St Vincents Institute of Medical Research, 17 August 2000
WO/2000/046390, T helper cell epitopes, University of Melbourne, CSL Ltd, Commonwealth Scientific and Industrial Research Organisation, QIMR Berghofer Medical Research Institute, and Walter and Eliza Hall Institute of Medical Research, 10 August 2000
WO/2000/046233, Pigment protein from coral tissue, University of Sydney, 10 August 2000
WO/2000/041730, A composition and method for the enhancement of the efficacy of drugs, Alchemia, 20 July 2000
WO/2000/040585, Cryptate compounds and methods for diagnosis and therapy, Australian Nuclear Science & Technology Organisation and Australian National University , 13 July 2000
WO/2000/040262, Novel agents and methods for treatment and diagnosis of ocular disorders, Flinders University, 13 July 2000
WO/2000/040258, Extracts of celery seed for the prevention and treatment of pain, inflammation and gastrointestinal irritation, International Celery Development Alliance Pty Ltd , 13 July 2000
WO/2000/040244, Use of phanquinone for the treatment or prevention of memory impairment, P.N. Gerolymatos S.A., 13 July 2000
WO/2000/039146, Miniribozymes active at low magnesium ion concentrations, Commonwealth Scientific and Industrial Research Organisation , 6 July 2000
WO/2000/037636, SOCS box containing peptides, Walter and Eliza Hall Institute of Medical Research , 29 June 2000
WO/2000/035478, Treatment of papillomavirus infections, University of Queensland, 22 June 2000
WO/2000/034497, Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors, Massachusetts General Hospital, University of Zurich, University of Nijmegen and Walter and Eliza Hall Institute of Medical Research , 15 June 2000
WO/2000/031115, Methods of identifying antigen gene sequences, Commonwealth Scientific and Industrial Research Organisation, 2 June 2000
WO/2000/028003, Avipox vector coding an HIV antigen and a cytokine, Virax and Australian National University, 18 May 2000
WO/2000/025801, Herbal compositions for treating gastrointestinal disorders, Chinese Medicines Scientific Consultants Pty Ltd, 11 May 2000
WO/2000/024413, A method of treatment, Walter and Eliza Hall Institute of Medical Research, QIMR Berghofer Medical Research Institute and University of Melbourne, 4 May 2000
WO/2000/024412, Use of VEGF-C or VEGF-D gene or protein to prevent restenosis, Ludwig Institute for Cancer Research and Helsinki University, 4 May 2000
WO/2000/023601, Delivery system for porcine somatotropin, Commonwealth Scientific and Industrial Research Organisation, University of Western Sydney and Pig Research and Development Corporation , 27 April 2000
WO/2000/021560, FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy, Ludwig Institute for Cancer Research and Helsinki University, 20 April 2000
WO/2000/021538, A method of modulating ion channel functional activity, Australian National University, 20 April 2000
WO/2000/020578, A method of modulating cell survival and reagents useful for same, Walter and Eliza Hall Institute of Medical Research, 13 April 2000
WO/2000/020444, Novel peptides, University of Queensland, 13 April 2000
WO/2000/020443, Novel peptides, University of Queensland , 13 April 2000
WO/2000/015654, Cyclised conotoxin peptides, University of Queensland, 23 March 2000
WO/2000/015254, Immunogenic compositions and uses thereof, Walter and Eliza Hall Institute of Medical Research, 23 March 2000
WO/2000/015243, A method of treatment and agents useful for same, University of Melbourne, 23 March 2000
WO/2000/015240, Anionic or cationic dendrimer antimicrobial or antiparasitic compositions, Starpharma, 23 March 2000
WO/2000/015214, Fc receptor modulators and uses thereof, Ilexus Pty Ltd, 23 March 2000
WO/2000/015193, Mousse composition, Soltec Research Pty Ltd, 23 March 2000
WO/2000/010608, Preventives/remedies for arteriosclerosis and post-PTCA reangiostenosis, Meiji Milk Products Co., 2 March 2000
WO/2000/009561, Monoclonal antibody inhibitor of GM-CSF, Il-3, Il-5 and other cytokines, and uses thereof, Medvet Science Pty Ltd, 24 February 2000
WO/2000/007620, Protease inhibitors for use in the treatment of psoriasis, Biotech Australia Pty Ltd, 17 February 2000
WO/2000/006720, A novel regulatory molecule and genetic sequences encoding same, Walter and Eliza Hall Institute of Medical Research , 10 February 2000
WO/2000/006108, Casein formulations for the delivery of bioactive constituents, Pacific Biolink Pty Ltd, 10 February 2000
WO/2000/004897, Bioimplant formulation, Peptech, 3 February 2000
WO/2000/004043, Protease susceptibility II, University of Sydney, 27 January 2000
WO/2000/003723, Polymeric compounds and methods of formulating same, Chemeq, 21 January 2000
WO/1999/065930, Vitamin B12 derivatives and methods for their preparation, Biotech Australia Pty Ltd, 23 December 1999
WO/1999/062955, Method of designing agonists and antagonists to EGF receptor family, Biomolecular Research Institute, Ludwig Institute for Cancer Research and Commonwealth Scientific and Industrial Research Organisation , 9 December 1999
WO/1999/058588, Process for microgel preparation, University of Melbourne , 18 November 1999
WO/1999/058569, Plasmin inhibitors from the Australian brown snake Pseudonaja textilis textilis, University of Queensland and National Institute of Biological Standards and Control, 18 November 1999
WO/1999/058563, Moraxella catharralis proteins, Cortecs, 18 November 1999
WO/1999/056697, Pharmaceutical composition, University of New South Wales, 11 November 1999
WO/1999/054350, Novel omega conotoxin peptides, University of Queensland, 28 October 1999
WO/1999/053923, Pharmaceutical composition, Soltec Research Pty Ltd, 28 October 1999
WO/1999/053915, Inhibition of gram positive bacteria, University of New South Wales, 28 October 1999
WO/1999/053050, Methods and means for obtaining modified phenotypes, Commonwealth Scientific and Industrial Research Organisation, 21 October 1999
WO/1999/050387, Vaccination modalities, Eimeria Pty Ltd, Queensland Department of Primary Industries, and Rural Industries Research and Development Corporation, 7 October 1999
WO/1999/049887, Use of protease inhibitors for treating skin wounds, Biotech Australia Pty Ltd, 7 October 1999
WO/1999/049029, Control of gene expression, Benitec Biopharma and Queensland Department of Primary Industries, 30 September 1999
WO/1999/048496, Therapy of estrogen-associated disorders, Novogen, 30 September 1999
WO/1999/045110, V-like domain binding molecules, Diatech Pty Ltd, 10 September 1999
WO/1999/044599, Therapeutic treatment for renal dysfunction, Eli Lilly, 10 September 1999
WO/1999/040117, Three-dimensional structures and models of Fc receptors and uses thereof, Ilexus Pty Ltd, 12 August 1999
WO/1999/036438, Human CMRF-35-H9 receptor which binds IgM, Sisters of Mercy in Queensland, 22 July 1999
WO/1999/036050, Compositions and method for protecting skin from UV induced immunosuppression and skin damage, Novogen, 22 July 1999
WO/1999/033485, Expression vectors and cell lines expressing Vascular Endothelial Growth Factor D, and method of treating melanomas, Ludwig Institute for Cancer Research, 8 July 1999
WO/1999/032597, Stable emulsions, Dow Corning, 1 July 1999
WO/1999/031132, Novel surface protein of Neisseria meningitidis, University of Queensland, 24 June 1999
WO/1999/029870, Porphorymonas gingivalis polypeptides and nucleotides, CSL Ltd, 17 June 1999
WO/1999/027959, Saponin adjuvant composition, Commonwealth Scientific and Industrial Research Organisation, 10 June 1999
WO/1999/027950, Compositions of Leukaemia Inhibitory Factor, Amrad, 10 June 1999
WO/1999/026971, Antimicrobial peptides, Victorian Dairy Industry Authority, 3 June 1999
WO/1999/024470, Mammalian milk growth factor, Gropep, 20 May 1999
WO/1999/023217, A novel gene and uses therefor, International Diabetes Institute and Deakin University, 14 May 1999
WO/1999/021975, Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor, Australian National University, 6 May 1999
WO/1999/019351, Novel NPY family member, Garvan Institute of Medical Research , 22 April 1999
WO/1999/018992, Oromucosal cytokine compositions and uses thereof, Pharma Pacific Pty Ltd, 22 April 1999
WO/1999/018974, Use of sulfated oligosaccharides in lowering blood triglyceride levels, Australian National University, 22 April 1999
WO/1999/016455, Mannose receptor bearing cell line and antigen composition, Austin Research Institute, 8 April 1999
WO/1999/016417, Buccal, polar and non-polar spray or capsule, Suda Pharmaceuticals, 8 April 1999
WO/1999/016406, Therapeutic method, University of Auckland, 8 April 1999
WO/1999/014321, Novel therapeutic molecules, Walter and Eliza Hall Institute of Medical Research, 25 March 1999
WO/1999/012969, Treatment of obesity, Metabolic Pharmaceuticals, 18 March 1999
WO/1999/012533, A method of modulating cellular activity, Medvet Science Pty Ltd, 18 March 1999
WO/1999/011703, Cross-linked particles, Biotech Australia Pty Ltd, 11 March 1999
WO/1999/011273, Use of sulfated oligosaccharides as inhibitors of cardiovascular disease, Australian National University , 11 March 1999
WO/1999/009981, Use of phanquinone for the treatment of Alzheimer's disease, P.N. Gerolymatos S.A., 4 March 1999
WO/1999/008994, Anti-cancer compounds, Peplin Biotech, 25 February 1999
WO/1999/008706, Recombinant porcine adenovirus vector, Commonwealth Scientific and Industrial Research Organisation and Pig Research Development Corporation, 25 February 1999
WO/1999/004826, Method for detection of fibrin clots, Australian National University , 4 February 1999
WO/1999/003886, Tropoelastin derivatives, University of Sydney, 28 January 1999
WO/1999/003328, Toxin genes from the bacteria Xenorhabdus nematophilus and Photorhabdus luminescens, Commonwealth Scientific and Industrial Research Organisation , 28 January 1999
WO/1999/002694, Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue, University of Queensland, 21 January 1999
WO/1999/002550, CTL epitopes from EBV, QIMR Berghofer Medical Research Institute, Commonwealth Scientific and Industrial Research Organisation, University of Melbourne, Walter and Eliza Hall Institute of Medical Research and CSL Ltd, 21 January 1999
WO/1999/001149, Health supplement, Sigma Pharmaceuticals, 14 January 1999
WO/1999/000406, Cyclic agonists and antagonists of c5a receptors and G Protein-Coupled Receptors, University of Queensland , 7 January 1999
WO/1999/000136, Control of acidic gut syndrome, University of New England , 7 January 1999
WO/1998/058939, Neurologically-active compounds, Polychip Pharmaceuticals Ptd Ltd and University of Sydney , 30 December 1998
WO/1998/056420, Ganglioside immunostimulating complexes and uses thereof, CSL Ltd, 17 December 1998
WO/1998/056387, Method of treatment of liver tumours and pharmaceutical compositions for use therein, University of New South Wales, 17 December 1998
WO/1998/053036, Alkylpolyglucosides containing disinfectant compositions active against Pseudomonas microorganism, Novapharm Research, 26 November 1998
WO/1998/052525, Sunscreen composition, Soltec Research Pty Ltd, 26 November 1998
WO/1998/051790, A novel nucleic acid molecule, Amrad, 19 November 1998
WO/1998/049192, Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with Porphyromonas gingivalis, University of Melbourne, Victorian Dairy Industry Authority and CSL Ltd, 5 November 1998
WO/1998/044129, Enhancement of immune response using targeting molecules, Queensland Institute of Medical Research, Commonwealth Scientific and Industrial Research Organisation, University of Melbourne, Walter and Eliza Hall Institute of Medical Research and CSL Ltd, 8 October 1998
WO/1998/042331, Mediation of circadian rhythms, Luminis Pty Ltd, 1 October 1998
WO/1998/042326, Fungal sulphur source and method of using the same, Commonwealth Scientific and Industrial Research Organisation and Australian Wool Research and Promotion Organisation , 1 October 1998
WO/1998/041218, An aqueous metal bicarbonate solution and method of use, Macquarie Veterinary Supplies Pty Ltd, 24 September 1998
WO/1998/040406, Calcium phosphopeptide complexes, University of Melbourne and Victorian Dairy Industry Authority, 17 September 1998
WO/1998/040081, Sulfated oligosaccharides having anticoagulant/antithrombotic activity, Australian National University, 17 September 1998
WO/1998/039021, Treatment and diagnosis of infertility using TGFβ or activin, Luminis Pty Ltd, 11 September 1998
WO/1998/038291, Component of bromelain, Cortecs, 3 September 1998
WO/1998/036772, Chelating immunostimulating complexes, CSL Ltd, 27 August 1998